229 related articles for article (PubMed ID: 22083619)
1. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).
Hedrich CM; Bruck N; Fiebig B; Gahr M
Rheumatol Int; 2012 Nov; 32(11):3525-30. PubMed ID: 22083619
[TBL] [Abstract][Full Text] [Related]
2. Extreme thrombocytosis in systemic juvenile idiopathic arthritis. A case report.
Iacono A; Sprocati M; Giuliani AL; Di Virgilio F; Borgna-Pignatti C; Maggiore G
Ital J Pediatr; 2019 Jun; 45(1):73. PubMed ID: 31234906
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
4. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
5. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
6. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
Baris HE; Anderson E; Sozeri B; Dedeoglu F
Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
Atemnkeng Ntam V; Klein A; Horneff G
Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061
[No Abstract] [Full Text] [Related]
8. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
9. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
Quartier P; Allantaz F; Cimaz R; Pillet P; Messiaen C; Bardin C; Bossuyt X; Boutten A; Bienvenu J; Duquesne A; Richer O; Chaussabel D; Mogenet A; Banchereau J; Treluyer JM; Landais P; Pascual V
Ann Rheum Dis; 2011 May; 70(5):747-54. PubMed ID: 21173013
[TBL] [Abstract][Full Text] [Related]
10. Perimyocarditis as first sign of systemic onset juvenile idiopathic arthritis treated successfully with anakinra: a case-based review.
Ciancia S; Cappella M; De Fanti A; Iughetti L
Acta Biomed; 2020 Sep; 91(4):ahead of print. PubMed ID: 33525302
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.
Laskari K; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2011 Jun; 13(3):R91. PubMed ID: 21682863
[TBL] [Abstract][Full Text] [Related]
12. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
13. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA).
Ohlsson V; Baildam E; Foster H; Jandial S; Pain C; Strike H; Ramanan AV
Rheumatology (Oxford); 2008 Apr; 47(4):555-6. PubMed ID: 18321945
[No Abstract] [Full Text] [Related]
14. Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience.
Pardeo M; Pires Marafon D; Insalaco A; Bracaglia C; Nicolai R; Messia V; De Benedetti F
J Rheumatol; 2015 Aug; 42(8):1523-7. PubMed ID: 26034148
[TBL] [Abstract][Full Text] [Related]
15. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
[TBL] [Abstract][Full Text] [Related]
17. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.
Ilowite N; Porras O; Reiff A; Rudge S; Punaro M; Martin A; Allen R; Harville T; Sun YN; Bevirt T; Aras G; Appleton B
Clin Rheumatol; 2009 Feb; 28(2):129-37. PubMed ID: 18766426
[TBL] [Abstract][Full Text] [Related]
18. Systemic onset juvenile idiopathic arthritis: a single center experience.
Sağ E; Uzunoğlu B; Bal F; Sönmez HE; Demir S; Bilginer Y; Özen S
Turk J Pediatr; 2019; 61(6):852-858. PubMed ID: 32134578
[TBL] [Abstract][Full Text] [Related]
19. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
20. [The importance of biologicals in the treatment of SoJIA].
Dückers G; Niehues T
Z Rheumatol; 2010 Aug; 69(6):505-15. PubMed ID: 20668866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]